Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stolte

Showing results (501-510 of 538) with videos related to

Pageof 54
Sort By:
Gut|May 8, 2008
Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagusO Pech, A Behrens, A May, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 18, 2006
Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD studyD Jaspersen, J Labenz, S N Willich, et al.
Gastroenterology|October 10, 1997
Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study GroupM Sackmann, A Morgner, B Rudolph, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2003
Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD StudyD Jaspersen, M Kulig, J Labenz, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2003
Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiativeM Kulig, A Leodolter, M Vieth, et al.
International Journal of Cancer|November 1, 1994
Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological typesM Blank, E Klussmann, S Krüger-Krasagakes, et al.
Alimentary Pharmacology & Therapeutics|July 18, 2006
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycinS Miehlke, K Hansky, W Schneider-Brachert, et al.
Digestive Diseases (Basel, Switzerland)|September 24, 2004
Radial distribution of dilated intercellular spaces of the esophageal squamous epithelium in patients with reflux disease exhibiting discrete endoscopic lesionsM Vieth, R Fiocca, J Haringsma, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2003
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistanceS Miehlke, W Schneider-Brachert, E Bästlein, et al.
Scandinavian Journal of Gastroenterology|March 4, 2005
Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda studyP Aro, J Ronkainen, T Storskrubb, et al.
Pageof 54

Showing results (501-510 of 538) with videos related to

Sort By:
Pageof 54
Gut|May 8, 2008
Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagusO Pech, A Behrens, A May, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 18, 2006
Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD studyD Jaspersen, J Labenz, S N Willich, et al.
Gastroenterology|October 10, 1997
Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study GroupM Sackmann, A Morgner, B Rudolph, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2003
Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD StudyD Jaspersen, M Kulig, J Labenz, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2003
Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiativeM Kulig, A Leodolter, M Vieth, et al.
International Journal of Cancer|November 1, 1994
Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological typesM Blank, E Klussmann, S Krüger-Krasagakes, et al.
Alimentary Pharmacology & Therapeutics|July 18, 2006
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycinS Miehlke, K Hansky, W Schneider-Brachert, et al.
Digestive Diseases (Basel, Switzerland)|September 24, 2004
Radial distribution of dilated intercellular spaces of the esophageal squamous epithelium in patients with reflux disease exhibiting discrete endoscopic lesionsM Vieth, R Fiocca, J Haringsma, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2003
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistanceS Miehlke, W Schneider-Brachert, E Bästlein, et al.
Scandinavian Journal of Gastroenterology|March 4, 2005
Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda studyP Aro, J Ronkainen, T Storskrubb, et al.
Pageof 54